BMS\' blockbuster Opdivo flys high and falls short in nonsmall cell lung cancer

BMS' blockbuster Opdivo flys high and falls short in non-small cell lung cancer

06:38 EDT 25 Jul 2019 | Pharmafile

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in the first-line treatment of non-small cell lung cancer (NSCLC), and not all of it was positive.

In the first of two announcements, it was revealed that, in part 1a of a Phase 3 trial, Opdivo in combination with low-dose Yervoy (ipilimumab) outmatched chemotherapy in improving overall survival (OS) in first-line NSCLC patients whose tumours expressed PD-L1 ≥1%, meeting the trial’s co-primary endpoint.

BMS\' blockbuster Opdivo flys high and falls short in nonsmall cell lung cancer

BMS' blockbuster Opdivo flys high and falls short in non-small cell lung cancer

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in the first-line treatment of non-small cell lung cancer (NSCLC), and not all of it was positive.

More From BioPortfolio on "BMS' blockbuster Opdivo flys high and falls short in non-small cell lung cancer"